Join the Oncology Voice Network. Join for Free
The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel
MSL territory excellence scientific acumen virtual presentation skills strategic territory planning MSL performance improvement

The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel


Share This Article


Summary

In this episode, Tom Caravela is joined by Julie Montiel to explore the nuances of MSL territory excellence and the critical role of scientific acumen. They delve into strategies for achieving scientific acumen and crafting effective, individualized territory plans. The conversation highlights the significance of pre-call and post-call planning in managing territories, as well as adapting strategies for virtual and digital engagements. Julie shares tips to enhance virtual presentation skills, concluding with a recap on creating a plan for territory excellence. The episode wraps up with closing remarks on the importance of key MSL strategies and a call to action for listeners.

My guest today is Julie Montiel, the National Scientific Director, Lymphoma/Myeloid MSL at The Janssen. We talk about the two most critical of MSL territory excellence.

In this episode we discuss:

  • Julie’s background
  • The two most critical elements
  • How MSLs improve their performance
  • What is scientific acumen 
  • Why is scientific acumen the most important element of territory excellence
  • What does excellence in scientific acumen look like?
  • Every territory is different
  • Applying principles to a virtual type of scenario
  • How MSLs bring all of these pieces of information together to build strategic territory excellence

Click for Source
MSL territory excellence, scientific acumen, virtual presentation skills, strategic territory planning, MSL performance improvement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN